<DOC>
	<DOC>NCT00625365</DOC>
	<brief_summary>The purpose of this registry study is to gather safety information on the current clinical use of and the safety of DEFINITY®</brief_summary>
	<brief_title>A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Inclusion criteria Patients who, in the investigator's opinion, require DEFINITY® echocardiography due to suboptimal, unenhanced images. Exclusion criteria Known hypersensitivity to perflutren, DEFINITY®, or other echo contrast agent. Prior SAE associated with perflutren, DEFINITY®, or administration of other echo contrast agent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>DEFINITY</keyword>
	<keyword>Safety</keyword>
	<keyword>Survelliance</keyword>
</DOC>